The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa

被引:10
作者
Snyman, L. C. [1 ]
Dreyer, G. [1 ]
Visser, C. [1 ]
Botha, M. H. [2 ]
van der Merwe, F. H. [2 ]
机构
[1] Univ Pretoria, Dept Obstet & Gynaecol, Fac Hlth Sci, Gynaecol Oncol Unit, ZA-0002 Pretoria, South Africa
[2] Univ Stellenbosch, Fac Med & Hlth Sci, Dept Obstet & Gynaecol, Unit Gynaecol Oncol, Cape Town, South Africa
来源
SAMJ SOUTH AFRICAN MEDICAL JOURNAL | 2015年 / 105卷 / 03期
基金
英国医学研究理事会;
关键词
SUSTAINED EFFICACY; PARTICLE VACCINE; FOLLOW-UP; PAPILLOMAVIRUS; ADOLESCENTS; TRIAL;
D O I
10.7196/SAMJ.8888
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Cervical cancer is a preventable disease with a high prevalence in South Africa (SA), where screening is opportunistic. Primary prevention is now possible through HPV vaccination. In VACCS 1 the feasibility of linking cervical cancer with HPV vaccination was demonstrated. Objectives. To investigate the feasibility of linking HPV self-testing with a two-dose HPV vaccination schedule and to compare results with VACCS I. Methods. The project was conducted in five schools in the South-West District of Tshwane, Gauteng, SA. Leaflet information on cervical cancer and screening was provided, with requests for consent and assent for a two-dose HPV vaccination of schoolgirls. Female caregivers were invited to take part in HPV self-screening. Results. Of 965 girls invited for vaccination, 519 (53.7%) had full consent and 518 (99.8%) received at least one vaccine dose. The invited uptake rate was 53.7% and 495 girls received both doses, giving a completion rate of 95.4% v. 82.6% in VACCS 1. Of 1 135 self-screen kits handed out, 560 (49.3%) were not returned. The mean age (standard deviation) of the 160 women who participated in self-screening was 38.7 (7.7) years. HPV testing was negative in 116 women (72.5%), 15 women (9.4%) tested positive for HPV 16 and/or 18, and 27 (16.9%) were positive for non-16/18 oncogenic HPV. Conclusion. Data from the VACCS projects suggest that school-based vaccine programmes can be successfully implemented. A two-dose schedule allowed for higher completion rates. Linking self-collected HPV screening to HPV vaccination is feasible, is a promising and viable screening strategy, and reached the appropriate age group for screening.
引用
收藏
页码:191 / 194
页数:4
相关论文
共 17 条
  • [1] Botha MH, 2015, SAMJ S AFR MED J, V105, P40, DOI [10.7196/SAMJ.8419, 10.7196/samj.8419]
  • [2] Predictors of HPV vaccine acceptability: A theory-informed, systematic review
    Brewer, Noel T.
    Fazekas, Karah I.
    [J]. PREVENTIVE MEDICINE, 2007, 45 (2-3) : 107 - 114
  • [3] Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach
    Brotherton, Julia M. L.
    Murray, Sharron L.
    Hall, Madeline A.
    Andrewartha, Lynne K.
    Banks, Carolyn A.
    Meijer, Dennis
    Pitcher, Helen C.
    Scully, Megan M.
    Molchanoff, Luda
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2013, 199 (09) : 614 - 617
  • [4] Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries
    Cuzick, Jack
    Arbyn, Marc
    Sankaranarayanan, Rengaswamy
    Tsu, Vivien
    Ronco, Guglielmo
    Mayrand, Marie-Helene
    Dillner, Joakim
    Meijer, Chris J. L. M.
    [J]. VACCINE, 2008, 26 : K29 - K41
  • [5] Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial
    Dobson, Simon R. M.
    McNeil, Shelly
    Dionne, Marc
    Dawar, Meena
    Ogilvie, Gina
    Krajden, Mel
    Sauvageau, Chantal
    Scheifele, David W.
    Kollmann, Tobias R.
    Halperin, Scott A.
    Langley, Joanne M.
    Bettinger, Julie A.
    Singer, Joel
    Money, Deborah
    Miller, Dianne
    Naus, Monika
    Marra, Fawziah
    Young, Eric
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (17): : 1793 - 1802
  • [6] Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities
    Gakidou, Emmanuela
    Nordhagen, Stella
    Obermeyer, Ziad
    [J]. PLOS MEDICINE, 2008, 5 (06): : 863 - 868
  • [7] Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
    Harper, DM
    Franco, EL
    Wheeler, CM
    Moscicki, AB
    Romonowski, B
    Roteli-Martins, CM
    Jenkins, D
    Schuind, A
    Clemens, SAC
    Dubin, G
    [J]. LANCET, 2006, 367 (9518) : 1247 - 1255
  • [8] Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes
    Heideman, D. A. M.
    Hesselink, A. T.
    Berkhof, J.
    van Kemenade, F.
    Melchers, W. J. G.
    Daalmeijer, N. Fransen
    Verkuijten, M.
    Meijer, C. J. L. M.
    Snijders, P. J. F.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (11) : 3983 - 3985
  • [9] ICO (Instinn Catal dOncologia) Information Centre on HPV and Cancer. South Africa, 2013, HUM PAP REL CANC FAC
  • [10] Human papillomavirus DNA testing on self-collected vaginal tampon samples as a cervical cancer screening test in a Gauteng population
    Mnisi, E. F.
    Dreyer, G.
    Richter, K. L.
    Horton, A.
    Snyman, L. C.
    [J]. SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2013, 5 (02) : S15 - S20